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Abstract
The ability of steroids to modulate high-affinity 5-HT transport was investigated using cell-based models which stably
manifest all known properties of this transport system. L-Estradiol (E2) exhibited noncompetitive, and possibly allosteric,
inhibition of both radiolabeled serotonin ([3H]5-HT) transport by, and radiolabeled cocaine congener ([3H]CFT) binding to,
this system. Such inhibitory effects were observed within short time courses and unlikely to result from genomic effects
normally ascribed to estrogen action. Rather, such nongenomic effects on 5-HT uptake were more akin to modulatory effects
of select steroid metabolites on other plasma membrane systems such as neurotransmitter receptors and ionic channels.
Beyond E2, preliminary examination of other steroid metabolites and synthetic steroid receptor agonists/antagonists revealed
that inhibition of 5-HT transport is additionally attributable only to estriol (E3, an E2 metabolite) and tamoxifen (a
nonsteroidal, E2 receptor antagonist). These findings indicate that the present form of transport modulation is only rendered
by select compounds and not a general property of steroidal and related agents. Assessments of covalent conjugates of E2
suggested that E2 interacts with the transporter protein at allosteric site(s) inaccessible from the extracellular domain. These
findings collectively suggest that steroid-mediated regulation of 5-HT transport may be a physiologically relevant
mechanism, and that antidepressant as well as psychostimulant effects in vivo may contain a steroidal component. ß 1999
Elsevier Science B.V. All rights reserved.
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1. Introduction
A key regulatory process of chemical neurotrans-
mission is the inactivation of neurotransmitters fol-
lowing their stimulated release. This inactivation
process is mediated by membrane-integral, high-af-
¢nity transport/reuptake systems which are relatively
speci¢c for individual neurotransmitters. Acetylcho-
line is the only known exception to this paradigm
because extracellular acetylcholine is ¢rst hydrolyzed
into acetate and choline, and choline is then seques-
tered by a speci¢c transport mechanism. Such trans-
port systems have access to the extracellular domains
of neuronal synaptic and somatic regions, as well as
of glial elements surrounding the synaptic clefts.
They share a number of functional similarities in-
cluding relatively high a⁄nities for their ligands
(when compared with the a⁄nities of amino acid
and sugar uptake systems), and dependence on ex-
tracellular Na and Cl3 ions [1]. These plasma mem-
brane systems are structurally and pharmacologically
distinct from intracellular transport systems which
sequester neurotransmitters into synaptic vesicles
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from cytoplasmic domains. In addition, some of
these plasma membrane transport systems are inti-
mately involved with neuropsychiatric disorders.
Most notably, the 5-HT transport system is a princi-
pal site of action of both antidepressants (tricyclics
and nontricyclics) and psychostimulants (e.g., co-
caine, amphetamine).
Exogenous steroid/retinoid hormones are known
to profoundly a¡ect a variety of neuronal e¡ector
mechanisms. These hormones can enter cells via dif-
fusion across the plasma membrane, and subse-
quently activate appropriate nuclear receptors to
function as transcriptional factors which regulate
the expression of target gene sequences. Such nuclear
e¡ects are generally detectable on the time scale of
hours or longer following hormone administration
(presumably due to rate limitations in conveying
transcriptional alterations to posttranslational e¡ec-
tor changes). Another form of steroid/retinoid hor-
mone action particularly pertinent to synaptic neuro-
transmission has been exempli¢ed by a variety of
steroid metabolites/analogs exerting regulatory ef-
fects on membrane e¡ector systems such as ion chan-
nels (e.g., Ca2 channels) and neurotransmitter re-
ceptors (including nAChR, GABAA receptor,
NMDA receptor) with time courses (seconds to mi-
nutes) far too brief to invoke signi¢cant transcrip-
tional/translational e¡ects [2,3]. These near-instanta-
neous, nongenomic e¡ects of hormones on neural
activities are not likely to be simply alterations of
plasma membrane biophysical properties that subse-
quently impinged on ion channels or receptor com-
plexes [4,5]. Rather, these e¡ects are more likely to
result from steroid association with speci¢c plasma
membrane sites [6], which may be structurally inher-
ent in the target channels/receptors. Beyond neuro-
transmitter receptors and ion channels, the ¢ndings
in this report will illustrate that neurotransmitter
transport systems are also subject to hormonal regu-
lation in vitro via nongenomic mechanism(s).
2. Materials and methods
2.1. Cell models of 5-HT uptake
Previous studies in this laboratory, on the struc-
tural and mechanistic properties of 5-HT transport,
have relied extensively upon cell-based models which
either endogenously or exogenously express this sys-
tem. These models provide signi¢cant experimental
advantages by their relative uniformity in activity,
ease of maintenance and continuous propagation.
More signi¢cantly, the 5-HT transport systems stably
expressed in these cell lines share essentially identical
kinetic, pharmacological and ion-dependence proper-
ties, and have demonstrated comparabilities with
CNS-derived models of 5-HT transport [7^10]. A
human placental trophoblastic cell line, JAR, was
previously shown to exhibit 5-HT transport activities
[11]. A transfectant cell line, L-14, was derived from
random transfection of human genomic DNA into
mouse L-M ¢broblasts [7], and has been useful in
de¢ning the common structural motifs of antidepres-
sants which are critical for interaction with the 5-HT
transporter [9]. L-14 cells and JAR cells were main-
tained in continuous culture and used for transport
assays by following procedures previously described.
Monkey kidney COS-1 cells transiently expressing
the cloned mouse brain SERT (mSERT) cDNA
(GenBank accession no. AF013604), following the
lipofection-mediated transfection procedure as previ-
ously described, also manifest the same transport
properties as the other two cell lines [10].
2.2. [3H]5-HT transport
Cultured cells were trypsinized and then plated
into 96-well plates for measurements of initial trans-
port velocities. Two to 3 days post-plating, when the
cells reached con£uence, they were rinsed twice with
oxygenated Krebs’ Ringer bu¡er (128 mM NaCl, 5.2
mM KCl, 2.1 mM CaCl2, 2.9 mM MgSO4, 5 mM
glucose, 10 mM Hepes, pH 7.4; supplemented with
0.5 mM pargyline and 0.5 mM ascorbate) and then
incubated at 37‡C with [3H]5-HT. At the end of the
incubation, excess radioligands were removed and
the cell-monolayers were washed three times with
excess Ringer’s bu¡er at room temperature. Incuba-
tions in the presence of 100 WM imipramine served to
measure nonspeci¢c uptake levels, and yielded the
same uptake levels as measured in untransfected
cells. Incubated cells were then lysed with 1% SDS
and transferred into counting vials for liquid scintil-
lation spectrometry. Additional wells were processed
in parallel and used for protein determination by the
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BCA method, in order to normalize the observed
uptake activities.
2.3. [3H]Cocaine congener binding
Initial studies indicated that radiolabeled 3L-(4-£u-
orophenyl)tropan-2L-carboxylic acid methyl ester
([3H]CFT) bound to the 5-HT transporter in both
mSERT-transfected COS-1 cells and L-14 cells in
concentration-saturable manners. Curiously, binding
activities were also detected in untransfected COS-1
and L-M cells, at levels substantially lower than
those of the transfected cells, and characterized by
nonsaturability (with increasing [3H]CFT concentra-
tions up to 50 nM) as well as both imipramine and
cocaine sensitivities (data not shown). The nature of
such binding sites in the untransfected cells were un-
clear. Speci¢c levels of [3H]CFT binding were opera-
tionally de¢ned as di¡erences in binding activities
measured in both transfected and correspondingly
untransfected cells. Con£uent cell monolayers in
96-well plates were used for equilibrium [3H]CFT
binding by the same procedure used for transport
studies, but with the following modi¢cations: incu-
bations were at 4‡C for 2 h (in order to reach equi-
librium); post-binding washes used ice-cold Ringer’s
bu¡er. By this approach, mSERT-transfected COS-1
cells exhibited a saturable binding pro¢le best char-
acterized by one binding site with an equilibrium Kd
of 21.3 nM, Bmax of 2.47 pmol/mg protein and Hill
coe⁄cient of 1.01. This binding activity was also
competitively inhibited by antidepressants and other
cocaine analogs. Similar ¢ndings were also attained
from L-14 cells (when using L-M cells for measuring
nonspeci¢c binding activities).
2.4. Materials
The expression vector used for heterologous ex-
pression of mSERT, pBK-CMV, was purchased
from Stratagene. Dulbecco’s modi¢ed Eagle medium,
lipofectamine and Opti-MEM medium were from
Gibco/BRL. De¢ned calf serum was obtained from
HyClone. [3H]5-HT (20^35 Ci/mmol), [3H]CFT (60^
87 Ci/mmol), [K-3H]AIB (10^25 Ci/mmol), D-
[3H]glucose (20^30 Ci/mmol) and [3H]cocaine (25^
50 Ci/mmol) were from New England Nuclear. All
hormone analogs/metabolites/conjugates were from
Sigma. The BCA protein quantitation kit was pur-
chased from Pierce.
3. Results
3.1. Acute hormone administration
L-14 cells, when exposed to various hormones con-
currently with [3H]5-HT for only 10 min, exhibited
signi¢cant inhibition of 5-HT transport by E2 be-
tween 1034 and 1038 M (Fig. 1), with an apparent
IC50 of 4.4 WM. The potency of E2 in this case was
quite similar to that of an earlier study demonstrat-
ing E2’s inhibition of 5-HT transport as discerned in
brain synaptosomes [12]. The other tested hormones
exhibited only modest inhibition even at 100 WM,
and therefore deemed not as e¡ective as E2. Studies
with JAR and mSERT-transfected COS-1 cells also
revealed that E2 was the only e¡ective hormone at
inhibiting 5-HT transport and with IC50 values com-
parable to that discerned from L-14 cells. The ap-
parent transport inhibition by E2 was unlikely to
be strictly a nonspeci¢c or ‘global’ membrane e¡ect
Fig. 1. Acute hormone e¡ects on [3H]5-HT uptake by L-14
cells. Initial uptake velocities were measured as the di¡erences
between [3H]5-HT (0.1 WM) incubations (at 37‡C for 10 min) in
the presence and absence of 100 WM imipramine. Cells were
cultured in normal media/sera. Hormones at the indicated con-
centrations were added when the uptake measurements were ini-
tiated in oxygenated Ringer’s bu¡er. Initial velocity (pmol/mg
per min) was calculated for each hormone treatment, and nor-
malized by control uptake velocity. Comparable ¢ndings were
also attained from JAR and mSERT-transfected COS-1 cells.
Each point is mean þ S.D. (n = 8).
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(e.g., alterations of membrane £uidity caused by ster-
oid di¡usion into the lipid bilayer) since all of the
hormones tested, including E2, have similar hydro-
phobic tendencies and comparable lipid-partitioning
capacities. Furthermore, in the same cells used for
5-HT transport studies, we have also observed that
E2 was less inhibitory on glucose uptake activities
(as measured by speci¢c uptake of D-[3H]glucose),
and not detectably inhibitory on system A of amino
acid uptake (as measured by speci¢c uptake of
[K-3H]AIB).
The apparently limited e⁄cacies of the other hor-
mones in transport inhibition initially suggested the
possibility that E2 might be mediating its inhibitory
e¡ect either via membrane-bound or intracellular es-
trogen receptors. Examination of estrogenic metabo-
lites (E1 and E3) and an estrogen receptor antagonist
(tamoxifen) revealed that, while estrone was ine¡ec-
tive, estriol (E3) and tamoxifen both inhibited SERT
activity with relatively comparable inhibitory poten-
cies (IC50 of E3 is 25.5 WM; that of tamoxifen is 16.9
WM). Based on these ¢ndings, it seemed unlikely that
conventional estrogen receptors mediated the ob-
served e¡ects, since they manifest widely varying af-
¢nities for these estrogenic agents [13,14]. Addition-
ally, the time course (10 min) of hormone treatment
in these studies were deemed inadequate for activa-
tion of nuclear receptor pathways.
3.2. Chronic hormone administration
The e¡ects on 5-HT transport of chronically ad-
ministering these hormones in culture were also ex-
amined. Only JAR cells were suitable for this partic-
ular study since the endogenous human SERT gene
is expressed through its appropriate, cis-regulatory
elements. Because of the short-term estrogenic e¡ects
on 5-HT transport (as shown in Fig. 1), chronic
hormone studies required that the JAR cells be main-
tained in specialized media devoid of estrogenic sub-
stances. It is well known that phenol red, which
serves as pH indicator in most culture media formu-
lations, is highly estrogenic [15]. The calf sera nor-
mally used to supplement the culture media also con-
tain steroids/retinoids and their metabolites which
can be e⁄ciently removed by charcoal stripping as
previously described [16]. To avoid interference from
these sources, JAR cells were maintained in culture
media deprived of phenol red, and supplemented
with charcoal-stripped calf sera for at least 48 h prior
to experimental use.
Under these conditions, progesterone and dexame-
thasone exhibited minimal e¡ects on 5-HT transport
activities; at concentrations above 1 WM, E2-medi-
ated inhibition became evident, consistent with E2’s
rapid inhibition of this system (as seen in Fig. 1). The
reduced levels of E2-mediated inhibition observed in
this case, relative to those seen during the acute ad-
ministration studies, may have resulted from hor-
mone metabolism during the prolonged incubation.
3,3P,5-triiodo-L-thyronine (T3) and all-trans retinoic
acid (RA) were highly stimulatory, and in dose-de-
pendent manners; vitamin D was intermediate be-
tween the other steroids and T3/RA (Fig. 2). These
observed e¡ects were not re£ective of changes in cell
number following hormone treatments. Because the
time course of hormone exposure in this study was of
su⁄cient length to allow activation of the respective
nuclear hormone receptors, the observed transport-
stimulatory e¡ects in this case might be attributable
to hormone-induced transcriptional changes of hu-
Fig. 2. Chronic hormone e¡ects on [3H]5-HT uptake activity in
JAR cells. Cells were cultured in medium deprived of phenol
red, and charcoal-stripped sera for at least 48 h prior to uptake
assay (to minimize cell exposure to estrogenic agents). Hor-
mones at the indicated concentrations were added to cells in
the modi¢ed culture medium. Uptake velocity was measured
for 48 h following hormone treatment by incubating cells with
0.1 WM [3H]5-HT for 10 min at 37‡C. Nonspeci¢c uptake level
was measured by inclusion of 100 WM imipramine. Measured
velocities were normalized by control levels measured in the ab-
sence of hormone addition. The same hormones were tested as
in Fig. 1. Each point is mean þ S.D. (n = 8).
BBAMEM 77556 2-2-99
A.S. Chang, S.M. Chang / Biochimica et Biophysica Acta 1417 (1999) 157^166160
man SERT in JAR cells. The long-term hormone
e¡ects were also notably distinct from those of the
short-term study, thereby further strengthening the
notion that the e¡ects seen in Fig. 1 represented non-
genomic regulation of 5-HT transport.
3.3. E2 modulation of [3H]5-HT transport
The nongenomic mechanism of transport inhibi-
tion attributed to E2 was further analyzed. Using
all three cell lines, varying concentrations (up to 30
WM) of E2 were incorporated into kinetic analysis
with di¡ering [3H]5-HT concentrations (0.1^0.4
WM). Dixon plot of the results attained under these
conditions revealed that the inverse-velocity pro¢les
all intersected on the x-axis, and not above said axis,
indicating that E2 inhibited transport via a noncom-
petitive (possibly allosteric) mechanism (Fig. 3). This
¢nding was consistent for all three cell lines, and at
variance with a competitive mechanism of transport
inhibition attributed to E2 in a prior study [12]. The
novelty of this ¢nding is that the vast majority of
known inhibitors for this transport system function
via competitive mechanism(s) and mutually compete
for common or overlapping binding site(s) on the
transporter [9]. The possibility of an allosteric site
on the transporter that modulates 5-HT transport
readily suggested that E2 might also modulate trans-
port binding of cocaine derivatives and antidepres-
sant agents [17^20].
3.4. E2 modulation of [3H]CFT binding
E2 was also examined for its ability to modulate
transport-inhibitor binding to the transport system.
After [3H]CFT binding to L-14 cells was allowed to
reach equilibrium (at 4‡C), the bound ligand was
allowed to dissociate into excess Ringer’s bu¡er at
room temperature for varying periods of time before
the levels of SERT-speci¢c [3H]CFT binding were
quantitated. As shown in Fig. 4, the presence of E2
(100 WM) in the Ringer’s bu¡er during the dissocia-
tion phase clearly altered the level of [3H]CFT re-
maining bound to the 5-HT transporter, presumably
because E2 allosterically increased the binding o¡-
rate. Imipramine, however, did not exhibit signi¢cant
e¡ect on the o¡-rate of bound [3H]CFT, consistent
with its action as a competitive inhibitor of 5-HT
uptake and [3H]CFT binding. These ¢ndings sug-
gested that E2 can allosterically and noncompeti-
Fig. 3. Noncompetitive inhibition of [3H]5-HT uptake by E2.
Dixon plot of initial uptake velocities measured in L-14 cells
using [3H]5-HT concentrations of 0.1, 0.2 and 0.4 WM, and
each [3H]5-HT concentration in the presence of E2 concentra-
tions ranging from 0 to 30 WM. Convergence of the inverse-ve-
locity pro¢les on the x-axis indicates a noncompetitive mecha-
nism of transport inhibition. Transport velocities were
measured at 37‡C for 10 min; inclusion of 100 WM imipramine
served to measure nonspeci¢c transport velocities. The same in-
hibitory mechanism was discerned in JAR and mSERT-trans-
fected COS-1 cells. Each value is mean þ S.D. (n = 6).
Fig. 4. Estrogenic modulation of [3H]CFT dissociation from
SERT binding. After binding of [3H]CFT (100 nM) to L-14
cells reached equilibrium (at 4‡C for 2 h), unbound radioligand
was removed and the cells were exposed at room temperature
to Ringer’s bu¡er alone (Control), Ringer’s plus 100 WM E2
(E2), or Ringer’s plus 100 WM imipramine (IMI) for the indi-
cated time before quantitation of bound [3H]CFT levels. The
di¡erential decreases of speci¢c binding activities, as functions
of time, were indicative of E2’s ability to increase the o¡-rate
of bound [3H]CFT, an ability attributable to a noncompetitive
inhibitor acting through allosteric mechanism(s). Comparable
results were observed with mSERT-transfected COS-1 cells.
Each point is mean þ S.D. (n = 6).
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tively inhibit cocaine analogs from binding to the 5-
HT transporter, in keeping with kinetic results indi-
cating that E2 noncompetitively and allosterically in-
hibited 5-HT uptake. In parallel binding studies, E2
exerted similar e¡ects on [3H]CFT binding to
mSERT-transfected COS-1 cells, while having no ef-
fect on binding to the untransfected COS-1 cells. The
presence of E2 reduced the level of bound [3H]CFT
in L-14 cells to almost that of background by 5 min,
when the binding dissociation was conducted at
room temperature. The same study, when conducted
at 4‡C, revealed no discernible di¡erences in speci¢c
binding levels until after 15 min, strongly indicating
that the mechanism of E2-mediated binding modula-
tion was also temperature dependent. The same bind-
ing/dissociation paradigm, when applied to
[3H]cocaine binding to the transport system, yielded
qualitatively comparable results. Thus, uptake and
binding studies both point to a consistent mechanism
whereby E2 allosterically modulates this transport
system, and such modulation presumably arises
from E2 interacting with the transporter at a site
distinct from the site shared by 5-HT and other
transport inhibitors.
3.5. Survey of steroid analogs/metabolites
As mentioned previously, E2, E3 and tamoxifen
exhibited inhibitory, nongenomically mediated activ-
ities toward 5-HT transport. Estrone, progesterone
and dexamethasone were relative ine¡ective in medi-
ating such activity. The extent to which other steroid
metabolites (in the biosynthetic pathways of proges-
tins, androgens and estrogens) might impact this
transport system was also examined. In addition,
synthetic steroid analogs (beclomethasone and dieth-
ylstilbestrol) and covalent E2 conjugates were also
tested. The ¢ndings (summarized in Table 1) indi-
cated that of all of the steroids/analogs tested, only
E2, E3 and tamoxifen were capable of rendering dis-
cernable transport inhibition at concentrations below
100 WM. Thus, inhibition of 5-HT transport is not a
general property of steroidal compounds and subtle
structural variations have dramatic impacts on trans-
port-inhibitory potencies. Lack of transport modula-
tion by diethylstilbestrol is further con¢rmation that
nuclear estrogen receptors are not likely to be in-
volved in the observed transport e¡ects, since dieth-
ylstilbestrol possesses high a⁄nity for the estrogen
receptor and mimics E2’s biological e¡ects in a vari-
ety of systems. Sulfate and glucuronide conjugates of
E2 also presented no inhibitory activity toward
transport. Since such covalent modi¢cations of E2
impede its partitioning into the membrane lipid bi-
layer, it is tempting to speculate that E2’s site of
action is not directly accessible from the extracellular
domain. Consistent with this notion, we have also
observed that an E2:BSA conjugate (which contains
about 30 moles of E2 per mole of BSA) possessed no
inhibitory activity at concentrations the equivalent of
500 WM E2. These observations provide further dis-
tinction between the E2-binding site on the trans-
porter from the site for which 5-HT and antidepres-
sants/cocaine congeners mutually compete (since the
latter is accessible from the extracellular domain).
4. Discussion
The in vitro ¢ndings presented herein collectively
indicate that select, estrogen-related steroids are ca-
Table 1
Inhibitory potencies of steroid metabolites/analogs
Steroid IC50 (WM)
Pregnenolone s 100









Estriol 25.5 þ 2.1
Diethylstilbestrol s 100







Each metabolite/analog was tested at several concentrations
ranging from 0.1 to 100 WM for inhibition of [3H]5-HT (0.1
WM) uptake velocity. Velocity measurements were conducted at
37‡C for 10 min; nonspeci¢c velocity was measured by inclu-
sion of 100 WM imipramine. Each value is mean þ S.D. (n = 6).
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pable of inhibiting 5-HT transport via a nongenomic
mechanism. The steroid-mediated e¡ect on 5-HT
transport extend beyond ligand translocation to in-
teraction with competitive inhibitors as well. Consis-
tent manifestations of this form of transport modu-
lation in three distinct cell models rule out the
possibility of cell-speci¢c factor(s) that contributed
to the observed transport e¡ects. Rather, this form
of transport inhibition is mediated by a noncompe-
titive and possibly allosteric mechanism which is
clearly distinct from those of antidepressants and
psychostimulants, and likely to involve direct inter-
action between the steroids and the 5-HT transport-
er. Both tricyclic and nontricyclic antidepressants
competitively inhibit 5-HT transport and share with
5-HT common or overlapping binding sites on the
transport system. Molecular modeling of the nontri-
cyclic antidepressant structures led to a prior pro-
posal that interaction with the 5-HT transporter at
the ligand-binding site required a speci¢c spatial sep-
aration of an amino group and a phenyl moiety, act-
ing as a transport pharmacophore [9]. Cocaine con-
geners function as competitive inhibitors of both
5-HT transport and antidepressant binding to the
system, and presumably share identical or overlap-
ping binding sites with antidepressants and 5-HT.
These congener structures also contain the previously
described pharmacophore (Chang, unpublished re-
sults). The antidepressants and psychostimulants all
interact with this transport system at domains acces-
sible from the extracellular domain. The structural
lack of the proposed pharmacophore in E2 (as well
as in E3), the apparent interaction of E2 with the
transporter at site(s) inaccessible from the extracellu-
lar domain, plus the noncompetitive nature of trans-
port/binding inhibition by E2 are all consistent with
its mechanistic distinction from other inhibitors of
5-HT transport.
Other studies have suggested that the central 5-HT
uptake system £uctuates during the estrus cycle [21].
Exogenous administrations of steroids such as L-es-
tradiol (E2) and progesterone (PG) can also e¡ect
brain region-speci¢c changes in 5-HT uptake. [22^
25]. Peripheral gonadectomies have been shown to
also alter the activity of this transport system in
brain region-speci¢c manners [26^29]. In light of
the present ¢ndings, such hormone e¡ects on 5-HT
transport in vivo are likely to represent both tran-
scriptional changes of the transporter gene (as eli-
cited by nuclear steroid hormone receptors) and non-
genomic modulations of transport functions (as
elicited by the steroid hormones directly). It is there-
fore of interest, in future studies, to re-examine hor-
monal e¡ects on 5-HT uptake in vivo in terms of
delineating the relative contributions of both ge-
nomic and nongenomic regulatory mechanisms.
The described ¢ndings are also consistent with
nongenomic, steroidal regulation of ion channel
and receptor activities in sharing several functional
commonalities. First, such steroid e¡ects tend to be
mediated by allosteric modulation of membrane ef-
fector systems [2,3,30^33]. Second, the time course of
such modulatory e¡ects are near-instantaneous; in
the case of ion channels, steroid-mediated e¡ects
can be observed within seconds of steroid application
[4,34]. Third, covalent conjugations (with sulfate,
glucuronide or lipid moieties) and even subtle struc-
tural alterations (as occur during steroid metabolism)
can dramatically and unpredictably alter the potency
of neuroactive steroids in this particular mechanistic
context [12,31,35,36]. Fourth, unlike steroid a⁄nities
for their respective nuclear receptors, half-maximal
concentrations of steroids in modulating channel/re-
ceptor activities often fall within 1^10 WM [5,37^39].
While this apparently low range of steroid potencies
on membrane e¡ector systems supports the notion
for lack of genomic involvement, the physiological
relevance of such modulatory phenomena is uncer-
tain since steroid/metabolite concentrations in vivo
are thought to rarely exceed the nM range (or at
least so in the general circulation).
Several possible explanations have been advanced
in order to preliminarily reconcile the apparent in-
consistency between endogenous steroid concentra-
tions and discernable potencies in imparting nonge-
nomic regulatory e¡ects on membrane e¡ector
systems. Steroid metabolite levels in the brain has
been shown to be signi¢cantly higher than those
quantitated in peripheral circulation [40] and exhibit
signi¢cant region-speci¢c variations [41,42]. CNS ste-
roid metabolite levels are subject to signi¢cant and
potentially rapid £uctuations during menstrual/es-
trous cycles and in response to induced stress [43].
Collectively, these observations suggest that CNS
levels of steroid metabolites have the potential to
reach levels capable of modulating channels and re-
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ceptors. Steroid metabolites are often sequestered by
binding proteins in both cytoplasmic and extracellu-
lar domains (which could render region-speci¢c var-
iations in steroid concentrations in the CNS), and a
large portion of each metabolite may also be cova-
lently conjugated into water- or lipid-soluble forms
[44]. Such sequestrations and covalent conjugations
can e¡ectively reduce the active or available concen-
trations of each metabolite at or near each mem-
brane e¡ector system, possibly allowing the local
concentration of each steroid to be drastically under-
estimated [32]. The overall structural similarities be-
tween the tested steroidal compounds suggest that
subtle changes in the basic steroid structure can dra-
matically alter the potency of 5-HT transport inhi-
bition. It is possible, therefore, that endogenous ste-
roids exist in the CNS which might be more potent
inhibitors of 5-HT transport than E2. Relevance of
these possible explanations to steroid-mediated regu-
lation of 5-HT transport in vivo requires additional
study.
Nongenomic mechanism of 5-HT transport mod-
ulation by endogenous steroids, as elucidated from
the studies described herein, might be better under-
stood with additional insights into the structural at-
tributes of this system. The noncompetitive and pos-
sibly allosteric e¡ects of E2 on both ligand transport
and cocaine binding processes, which are likely to
extend to antidepressant interactions with SERT as
well, might be mediated through E2-induced confor-
mational changes in the transporter. The exact qua-
ternary structure of the active transport complex,
and its possible perturbations by E2, also remain to
be de¢ned. Further, it will be of interest to examine
the general applicability of this form of transport
modulation to other neurotransmitter transport sys-
tems. Given the intimate link between the 5-HT
transport system and several neuropsychiatric disor-
ders (e.g., depression, substance abuse and addic-
tion), the present ¢ndings also suggest the provoca-
tive possibility of endocrine involvement in the
underlying etiology or progression of these disorders,
and may preliminarily substantiate the long-held be-
lief that gender-speci¢c distinctions exist in such dis-
orders. Further, steroid-mediated modulation of in-
hibitor-binding indicates that endocrine functions
may impact the e⁄cacy of antidepressant therapies
targeted speci¢cally toward this transport system, the
psychostimulant e¡ects mediated by 5-HT transport,
as well as individual susceptibilities to substance
abuse/addiction. These issues will be better assessed
through in-depth understanding of the physiological
signi¢cance of steroid-mediated regulatory impacts,
both genomically and nongenomically, on 5-HT
transport.
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